Dysregulated expression of TGF-β signaling has been reported in many cancers such as hepatocellular carcinoma, colon, prostate, lung, and breast cancers (Sheen et al., 2013; Zhao and Chen, 2014; Villalba et al., 2017). Here, TGFB1 is linked to breast carcinoma.